Last update 02 Nov 2026
CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

Subsidiary Company|1997|Hebei Sheng, China|
www.e-cspc.com

Overview

Tags

Neoplasms
Endocrinology and Metabolic Disease
Hemic and Lymphatic Diseases
siRNA
Small molecule drug
Liposomal Drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease6
Neoplasms4
Nervous System Diseases2
Immune System Diseases2
Hemic and Lymphatic Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
siRNA5
Small molecule drug4
Chemical drugs1
Herbal medicine1
Antibody drug conjugate (ADC)1
Top 5 TargetCount
GR x β2-adrenergic receptor1
PCSK9(Proprotein convertase subtilisin kexin type 9)1
HER2 x Tubulin1
ANGPTL3(Angiopoietin like 3)1
C5(Complement C5)1

Related

13
Drugs associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Aprocitentan
Target
ETA x ETB
Mechanism
ETA antagonists [+1]
Active Org.
Idorsia Pharmaceuticals Deutschland GmbH [+4]
Originator Org.
IDORSIA LTD
Active Indication
Essential Hypertension [+2]
Inactive Indication
Chronic Kidney Diseases [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date19 Mar 2024
Mitoxantrone Hydrochloride liposomal
Target
Top II
Mechanism
Top II inhibitors
Active Org.
CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd. [+4]
Originator Org.
CSPC Pharmaceutical Group Ltd.CSPC Pharmaceutical Group Ltd.
Active Indication
Peripheral T-Cell Lymphoma [+33]
Inactive Indication
Adult Lymphoblastic Lymphoma [+29]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date01 Jun 2021
Shuxuening injection
Target-
Mechanism-
Active Org.
CSPC Yinhu Pharmaceutical Co., Ltd.CSPC Yinhu Pharmaceutical Co., Ltd.
Originator Org.
CSPC Yinhu Pharmaceutical Co., Ltd.CSPC Yinhu Pharmaceutical Co., Ltd.
Active Indication
Angina Pectoris [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date16 Jul 2020
71
Clinical Trials associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
CTR20262801
/ RecruitingPhase 2
在轻中度原发性高血压参与者中评价SYH2062注射液疗效和安全性的多中心、随机、双盲、安慰剂对照的II期临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy and safety of SYH2062 injection in participants with mild to moderate essential hypertension.
NCT07640217
/ Not yet recruitingPhase 2
A Phase II Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
NCT07735117
/ Not yet recruitingPhase 3IIT
A Prospective, Multicenter, Randomized Controlled Clinical Study of Mitoxantrone Hydrochloride Liposome, Subcutaneous Cytarabine and G-CSF Combined With Venetoclax Versus Azacitidine Combined With Venetoclax in the Treatment of MDS-IB2 and Newly Diagnosed Adult Secondary or Elderly AML
100 Clinical Results associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
0 Patents (Medical) associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
100 Deals associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
100 Translational Medicine associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
1
Phase 1
Phase 2
3
3
Phase 3
NDA/BLA
3
2
Approved
Other
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free